Product News

BONTAC’s NMNH: The Next-Generation NAD+ Enhancer

BONTAC is leading the way with their NMNH product, a groundbreaking advancement in NAD+ enhancement. As the reduced form of beta-nicotinamide mononucleotide (NMN), NMNH significantly outperforms NMN in boosting NAD+ levels. Naturally present in the kidney, NMNH converts rapidly into NAD+ within cells, offering superior efficiency and effectiveness. BONTAC’s commitment to innovation is evident in their patent-grade NMNH and cutting-edge production techniques.

Superior NAD+ Enhancement

BONTAC’s NMNH offers a more potent solution for elevating NAD+ levels compared to NMN. The conversion rate and concentration of NAD+ achieved with NMNH are over twice that of NMN. This enhanced capability allows for a more significant increase in NAD+ levels across various tissues, promoting optimal cellular health and function. BONTAC’s focus on NMNH ensures that users experience the full benefits of advanced NAD+ enhancement.

Pioneering Production and Patented Quality

BONTAC stands out as the first to introduce NMNH into mass production, setting new industry standards. Their NMNH product is of patent-grade quality (Patent No.: ZL 2024 1 0452498.9), reflecting their dedication to excellence and innovation. Utilizing a leading enzymatic process, BONTAC ensures that their NMNH maintains high purity and effectiveness. This pioneering approach highlights BONTAC’s role as a leader in NAD+ enhancement technology.

Versatile Product Forms

BONTAC offers NMNH in a variety of forms, including lyophilized powder, crystallized powder, amorphous, calcium salt, and eutectic. This range of forms caters to diverse needs and applications, making it easier for users to incorporate NMNH into their health regimens or products. BONTAC’s versatile NMNH options provide flexible solutions to meet specific requirements, whether for direct supplementation or formulation purposes.

Conclusion

BONTAC’s NMNH represents a significant advancement in NAD+ enhancement, surpassing beta-nicotinamide mononucleotide (NMN) in both efficacy and versatility. With their patent-grade NMNH and innovative production methods, BONTAC is at the forefront of NAD+ enhancement technology. Their commitment to quality and innovation ensures that users receive the highest benefits from NMNH, solidifying BONTAC as the premier choice for advanced cellular health solutions.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button